Redcare Pharmacy: The Bundesrat Ballot That Could Reshape Online Pharmacy Economics

Redcare stock has fallen 56% from highs as a German transport decree risks banning mail-order drug delivery, despite strong Q1 growth and 67% online prescription market share.

Germany’s upper house of parliament votes today on a long-awaited pharmacy reform, and for Redcare Pharmacy the stakes could hardly be higher. Buried inside the legislative package is a separate transport regulation that the company’s chief executive calls a “systemic breach” — one that risks strangling the very supply chain on which its digital prescription empire depends.

The political drama plays out against a grim backdrop for shareholders. Redcare’s stock closed on Thursday at €49.22, managing a modest 2.16% gain for the day but still nursing a nearly 49% loss over the past twelve months. From its summer 2025 all-time high of €112.10, the equity has shed more than 56% of its value. Year to date, the decline stands at 27%.

That rout reflects far more than company-specific weakness. It is the product of a regulatory tug-of-war that has left Berlin paralysed.

The real risk lies in the fine print

The main Apothekenstärkungsgesetz would expand the powers of brick-and-mortar pharmacies — allowing them to vaccinate, perform blood draws and dispense certain prescription drugs more freely. For Redcare, which derives the lion’s share of its revenues from digital prescriptions and partnerships with local chemists, the law initially appeared to offer a catalyst.

Yet the medical establishment has pushed back hard, arguing that the reforms encroach on physicians’ professional turf. The stand-off has left the legislation in limbo. Far more threatening, however, is a separate administrative decree that tightens rules for the transport of medicines. Logisticians would face blanket temperature monitoring and rigorous documentation obligations. Redcare CEO Olaf Heinrich has warned bluntly that the measure amounts to a ban on mail-order delivery through the back door — a move that would directly imperil a business model used today by over 26 million German patients.

Growth numbers tell a different story

Beneath the political noise, the operational engine is firing well. In the first quarter, Redcare generated revenue of nearly €850 million, while operating profit surged 58% to €14.4 million. The company reaffirmed its full-year guidance. Its grip on the online prescription market remains dominant at 67%, and the steady shrinkage of Germany’s physical pharmacy network — down to just over 16,500 outlets in March — continues to push more script volume onto digital channels.

Competition is nonetheless intensifying on the over-the-counter front. Drugstore chain dm has launched its own platform, dm-med, and Rossmann is building a rival online pharmacy. Redcare’s management has already responded by trimming its medium-term margin target for the OTC segment from above 8% to more than 5%.

Meanwhile, the broader market environment is in flux. Australia’s Wesfarmers Health is pouring money into digital capabilities aimed at an ageing population, and competition authorities in Ireland are examining pharmacy pricing transparency — signs that the industry is entering a period of structural upheaval.

Analysts look past the noise

Despite the stock’s collapse, the professional consensus remains broadly constructive. Seven of nine analysts covering Redcare rate the shares a buy. The average price target stands at roughly €95, implying more than 90% upside from current levels. Deutsche Bank’s Jan Koch argues that the regulatory uncertainties are already discounted in the equity.

What happens in Berlin today will provide the first clear signal. If the Bundesrat approves the reform, attention will shift swiftly to the logistics decree — and how strictly its provisions are ultimately drafted. For a company that has proven it can deliver strong operational results, the difference between a benign and a punitive regulatory outcome could determine whether the stock’s 49% annual loss is a buying opportunity or a prelude to further pain.